Back

Relative efficacy of acoramidis, tafamidis and vutrisiran in patients with transthyretin amyloid cardiomyopathy: a multilevel network meta-regression

10 May 2026 (11:30 - 12:15)
Organised by: Logo
Congress Presentation Part of: Phenotyping, prognosis, and therapeutic strategies in infiltrative and hypertrophic cardiomyopathies Clinical Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Antoine Jobbe Duval

Medipole Lyon-Villeurbanne, Villeurbanne (France)

6 More presentations in this session

Presentation thumbnail
Prediction of genotype positivity in patients with Hypertrophic Cardiomyopathy: validation of the Mayo score in a large Portuguese HCM cohort
Doctor S. Azevedo (Lisbon, PT)
Abstract Slides
Presentation thumbnail
The impact of sodium glucose cotransporter 2 inhibitors in hypertrophic cardiomyopathy: systematic review and meta-analysis
Associate Professor T. Chendey (Uzhgorod, UA)
Abstract Slides
Presentation thumbnail
Prevalence of transthyretin amyloid cardiomyopathy in at-risk outpatients: real-world data from a german multicentre ambulatory registry (BNK ATTRact Registry)
Doctor S. Schwarting (Munich, DE)
Abstract Slides
Presentation thumbnail
Conventional heart failure medication in immunoglobulin light-chain cardiac amyloidosis
Doctor C. Nitsche (Vienna, AT)
Abstract Slides
Presentation thumbnail
Left ventricular mass including papillary muscles and trabeculations has greater prognostic value compared with maximum left ventricular wall thickness in hypertrophic cardiomyopathy
Doctor H. Lee (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Phenotyping, prognosis, and therapeutic strategies in infiltrative and hypertrophic cardiomyopathies

The Event

Event poster

Heart Failure 2026

10 May 2026 11:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources